NBT Bancorp Inc. reported a record net income of $58 million for Q3 2026, up from $54.5 million in Q3 2025, with diluted earnings per share rising to $1.11. The bank saw loan growth, increased net interest income, and improved net interest margin, reflecting strong business execution. It declared a fourth-quarter cash dividend of $0.40 per share, an 8.1% increase from the previous year, marking 14 consecutive years of dividend growth. These results position NBT well for continued customer service and shareholder value creation.
NBT Bancorp Inc. reported record Q3 2026 results. For readers following Financials, here is Pluang's market snapshot as of Oct 28, 2026 03:12 WIB: 78 of 142 US Financial stocks rose, 63 fell. Notable movers include PSEC at USD 1.55 (+4.36%, 100% buy orders, 79 days hold), AFRM at USD 72.41 (+4.20%, 21 days hold), and WU at USD 5.95 (-4.19%, 98% buy orders, 98 days hold).
The global drone defense system market is projected to grow from $4.72 billion in 2025 to $18.19 billion by 2030, driven by increasing unauthorized drone incidents and demand for advanced detection and countermeasure technologies. Growth is fueled by...
Eli Lilly has outpaced Novo Nordisk in the GLP-1, obesity, and Type 2 Diabetes market, achieving a $1.21 trillion valuation. While Novo Nordisk's share price has fallen back after earlier gains and revenue growth remains flat, its management's strate...
argenx SE announced it will stop its Phase 3 UNITY study of efgartigimod subcutaneous for moderate-to-severe Sjögren's disease after an independent committee found the trial unlikely to meet its primary goal. This decision caused the company's stock ...
Pomerantz LLP is investigating DaVita Inc. for potential securities fraud following a sharp stock price drop triggered by a new U.S. federal strategy targeting the dialysis market. The Department of Health and Human Services announced a plan to incre...
Pomerantz LLP is investigating ClearPoint Neuro and its executives for possible securities fraud following a significant stock price drop. The decline occurred after ClearPoint's partner, uniQure, announced that their Huntington's disease treatment f...
